Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center
Jeffrey Xia(Stanford University), Sukeshi Patel Arora(The University of Texas MD Anderson Cancer Center), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center)
Cited by 5
Related Papers
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
|EBioMedicine|2023|275
Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer
|European Urology|2018|224
Strain-Dependent Variation in 18S Ribosomal DNA Copy Numbers in <i>Aspergillus fumigatus</i>
|Journal of Clinical Microbiology|2009|197
A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
|Experimental Gerontology|2018|168
Acarbose improves health and lifespan in aging HET3 mice
|Aging Cell|2019|145